GV is Alphabet-backed but operates as an autonomous, returns-first multi-stage venture firm investing across technology and life sciences. It is especially active in AI-native, technically differentiated companies and combines long-duration capital with hands-on operating support, while maintaining strict discipline on valuation and price-to-value fit.
Evaluation weights
How much weight this firm places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Biased toward technically deep founders over purely commercial teams
- Willing to invest early in frontier technology if the moat is real
- More flexible on round leadership than many firms
- Aggressive on category-defining opportunities but conservative on price
Pitch difficulty
How hard it is to get a meeting and close funding from this firm.
- Funded / yr
- 90Deals closed in a typical year.
- Led / yr
- 33Rounds led in the last 12 months.
- Pitches / yr
- ~8684Decks reviewed in a typical year.
- Acceptance rate
- 1.0%Share of pitches that get funded.
Estimated — public data is not fully disclosed.
Why it's hard
- Top-tier brand attracts highly competitive deal flow
- High bar for technical moat and founder quality
- Invests across many sectors but only in companies with outsized market potential
- Strict valuation discipline eliminates many otherwise attractive deals
GV sees high deal volume globally, invests over $1 billion annually, and has flexibility across stages and sectors, but it sets a high bar on founder quality, technical differentiation, market scale, and valuation discipline. The combination of brand access, multi-stage capital, and a returns-first mandate means it can choose from the best opportunities and walk away from overpriced deals.
Green flags
What drives a yes for this firm.
- Exceptional founders with strong technical depth and ambition
- Clear technical moat or step-change product advantage
- Large, durable market with strong timing tailwinds
- Attractive value-to-price ratio relative to stage and company quality
- Potential for a long-term multi-stage relationship
Red flags
What kills deals and gets a fast no.
- Pricing the round too aggressively relative to traction or stage
- Presenting an AI story without real technical differentiation
- Targeting a market that is too small or too short-lived for venture-scale returns
- Lack of conviction in the founding team or weak founder-market fit
- Later-stage metrics that do not support scalability, retention, or category leadership
How to win
Patterns that lead to successful pitches.
- Lead with the founder's unique technical insight and why this team is uniquely suited to win
- Show a non-obvious technical moat, not just strong positioning or branding
- Frame the company as attacking a very large market with durable tailwinds, especially around AI or infrastructure shifts
- Be explicit about why the current round price offers compelling upside relative to stage and traction
- Demonstrate openness to a long-term, multi-stage partnership and use of GV's operating platform
Fund strategy & identity
Who they are and how they operate.
- Invests across Seed, Series A, Series B, Series C, and Growth with flexible ownership targets
- Backs companies across enterprise, consumer, frontier tech, fintech, and life sciences
- Uses long-term, single-LP capital to support companies across multiple rounds
- Applies hard valuation discipline, passing when price does not match stage, quality, or upside
- Pairs capital with platform resources in design, engineering, marketing, and talent
Firm identity
Investment focus
Industries, themes, and typical ARR expectations.
Industries
Investment themes
Typical check by stage
Typical ARR by stage
Investment thesis
Core beliefs and strategy behind their investing approach.
GV is a multi‑stage venture firm that invests across industries with a long‑term orientation—"decades, not rounds." Backed solely by Alphabet, the firm operates autonomously and is financially driven, able to back competitors to Google while giving portfolio companies access to Google talent and technology when useful. Its sector focus spans AI, enterprise, consumer, frontier technology, and life sciences, with roughly 80% of new investments classified as AI‑native. GV maintains a strong life‑sciences practice and looks for ideas that require deep technical differentiation and long‑term capital support. Geographically, GV backs startups in North America, Europe, and Israel, with a dedicated European hub in London and over $1 billion invested in European startups since 2014. The firm’s core belief is that value is created by combining founder empathy, hands‑on company‑building resources (design, engineering, marketing, talent) with selective access to Google’s network. GV targets opportunities that demand multi‑stage relationships and technical moats, while discarding deals where the price does not reflect stage or quality. The firm positions itself as a returns‑first investor rather than a strategic corporate arm, aiming to be a partner of choice irrespective of the eventual acquirer.
Decision patterns
How they evaluate and make investment decisions.
GV places founder quality and technical differentiation at the top of its checklist, weighing market size and timing second, and scrutinizing valuation and price‑to‑value ratio as a hard constraint. Tom Hulme emphasizes that the firm invests purely for financial return and is "relaxed" about leading versus joining syndicates, preferring entry into the best companies over ownership rules. The firm passes on AI deals when the value‑to‑price ratio does not work. Internally, partners are empowered to make convictions with few internal blocks; David Krane notes they invest over a billion dollars a year with high volume. Relationship‑driven conviction is evident in examples like the $10 M Series A in Universe, where GV’s partner joined the board. Early‑stage decisions heavily weight team and product potential, while later stages incorporate traction and scalability, but price discipline remains pivotal. GV favors large, durable markets where AI or other frontier tech creates step‑change opportunities and avoids overpaying when stage, price, or quality misalign.
Risk appetite
GV exhibits a high‑conviction, flexible risk appetite. It is comfortable backing ultra‑early, pre‑revenue life‑science or frontier‑tech ideas as well as writing massive growth checks (e.g., the $257.79 M Uber round). The firm frequently leads seed and Series A rounds but will co‑lead or follow when that maximizes access and outcomes. Its patient‑capital model—backed by a single LP and a long‑term horizon—allows it to take on risk, yet partners stress valuation discipline, explicitly walking away from deals where price does not align with stage or quality. Overall, GV is aggressive in technology bets (especially AI) but remains conservative on pricing, balancing bold platform investments with rigorous value‑to‑price assessment.
Notable investments
Key portfolio companies and why they fit the thesis.
- Blue Water AutonomyLeadFrontier defense autonomy leveraging AI perception aligns with GV's AI and frontier-tech conviction. GV led the Series A (Dave Munichiello).
- Mechanical OrchardLeadEnterprise modernization platform with AI-forward software migration. GV led the $50M Series B.
- MetaviewLeadAI-native hiring platform. GV led the $35M Series B.
- ComplyanceLeadAgentic AI for governance, risk and compliance. GV led the $20M Series A (Feb 2026).
- SambaNovaLeadAI infrastructure and hardware venture. GV co-led the 2018 $56M Series A with Walden International.
- EpiBiologicsLeadNovel extracellular protein degradation platform aligns with GV's life-sciences investment theme.
- AttioLeadAI-native CRM; GV led Attio's $52M Series B (Aug 2025).
- DriverLeadAI-driven technical documentation tool accelerates enterprise productivity, fitting GV's AI tooling thesis.
- TranslucentLeadAI applied to healthcare finance. GV led the $27M Series A (March 2026).
- Guild.aiLeadCollaborative intelligence platform aligns with GV's AI apps and developer-tools investment theses.
Co-invested with
Other firms in this catalog who've backed the same companies.
No catalog overlap found yet. Co-investors are derived from each firm's notable investments — connections may surface as more firms are added.
Partners
Full firm roster — key partners, partners, and the wider team.
Key partners
David Krane
CEO & Managing Partner
Google Ventures
David Krane is CEO and Managing Partner at GV, where he leads global activities and invests in consumer-focused companies.
Dave Munichiello
Managing Partner
Google Ventures
Dave Munichiello is a Managing Partner at GV leading the firm's tech investing team across consumer, enterprise, and frontier areas.
Krishna Yeshwant
Managing Partner
Google Ventures
Krishna Yeshwant is a Managing Partner at GV and co-leads its life sciences group.
Tom Hulme
Managing Partner
Google Ventures
Tom Hulme is a Managing Partner at GV, head of Europe, and co-lead of the firm's global tech investing team.
Karim Faris
General Partner
Google Ventures
Karim Faris is a GV general partner investing in enterprise software, analytics, AI, and security. He has been with GV since its inception.
Erik Nordlander
General Partner
Google Ventures
Erik Nordlander is a general partner at GV investing in enterprise software and frontier technology. His focus areas include developer tools, cloud infrastructure, and machine learning.
Crystal Huang
General Partner
Google Ventures
Crystal Huang is a general partner at GV focused on SaaS, infrastructure, and AI. She has a particular interest in product-led and developer-led adoption strategies.
Anthony Philippakis
General Partner
Google Ventures
Anthony Philippakis is a General Partner at GV investing at the intersection of life sciences and machine learning. He is a physician, genomicist, and data scientist with prior cardiology training at Brigham and Women's Hospital.
Partners
Luna Schmid
Partner
Google Ventures
London-based GV partner investing in enterprise, consumer, and AI technology companies.
Elena Sakach
Partner
Google Ventures
GV partner investing across fintech, software, and AI from the San Francisco office.
Brendan Bulik-Sullivan
General Partner
Google Ventures
GV life sciences general partner with a statistical genetics and ML background.
Michael McBride
General Partner
Google Ventures
GV general partner backing enterprise, open-source, and AI startups after operating roles at GitLab and Meraki.
Karthik Ardhanareeswaran
Partner
Google Ventures
GV life sciences partner with prior quant finance and bioinformatics research experience.
Sherry Chao
Partner
Google Ventures
GV life sciences partner with Goldman Sachs and Broad Institute experience.
Vidu Shanmugarajah
General Partner
Google Ventures
London-based GV general partner backing early-stage technology startups.
Issi Rozen
General Partner
Google Ventures
GV life sciences general partner focused on biotech company formation and early-stage investing.
Ben Robbins
General Partner
Google Ventures
GV general partner investing in healthcare delivery and neuropsychiatric therapeutics.
Sangeen Zeb
General Partner
Google Ventures
GV general partner focused on AI and enterprise investments.
Frederique Dame
General Partner
Google Ventures
General Partner at GV investing across consumer, AI, life sciences, and women’s health after product leadership roles at Uber and Yahoo.
David Schenkein, MD
General Partner
Google Ventures
GV life sciences general partner and physician-investor focused on therapeutics and healthcare innovation.
Team
Rishi Modi
Associate
Google Ventures
GV associate investing across AI applications and infrastructure.
Anika Gupta Vatsa, PhD
Principal
Google Ventures
GV principal investing in biotech companies developing new medicines.
Mounisha Anumolu
Associate
Google Ventures
New York-based GV associate focused on AI investments.
Public voice
Notable statements and public positions.
- “GV operates on long time horizons and deals in decades, not rounds.”
- “Our partnership conversations center not around deals or funding rounds, but around the highest‑potential humans we meet each week. We seek out the most curious and impactful people across tech – and then build long‑lasting relationships of trust and respect.”
- “No question: we’re early… This is a pitch clock that we’ve never seen before. This game is moving incredibly quickly, for better and for worse.”
Similar firms
Firms with overlapping stage and industry focus.

Thrive Capital
0.3%
Bessemer Venture Partners
0.2%
Lightspeed Venture Partners
0.8%
